Sugen's SU101

26 May 1996

- Sugen's malignant glioma treatment SU101 has shown early promise in a Phase I dose-escalation trial. Of 24 patients who have completed their first cycle of therapy, 13 have continued into extended treatment based on stable disease or better, demonstrated by physical examination and magnetic resonance imaging. Two patients exhibited decreases in tumor cross-sectional area of 43% and 49% respectively. Another Phase I trial in poor-prognosis solid tumor patients has also started.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight